LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology companydevoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research & Development Day to provide an update on current late-stage ocular programs.
The presentations will begin at 7:30 a.m. Eastern Time on Thursday, February 28, 2019 in New York, New York.
A live webcast of the presentation and slide deck will be available via the Company's Investor Relations website at http://ir.aldeyra.com. Following the live webcast, an archived version will be available on the website until February 28, 2020.
About Aldeyra TherapeuticsAldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy, retinal disease, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Corporate Contact:David McMullinAldeyra Therapeutics, Inc.Tel: 781-761-4904 ext. 218 email@example.com
Investor Contact:Chris BrinzeyWestwicke PartnersTel: 339-970-2843Chris.firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-host-2019-research--development-day-300793645.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!